- On Aug 31, ACIU reported mixed p2 Alzheimer's Disease (AD) trial data.
- While comparing ACIU and ANVS' AD trial data, some ANVS investors on Stocktwits forum seem unclear about ANVS' p2a data.
- I take a look at ANVS' latest presentation at the Biomarkers for Alzheimer's Disease Summit 2021 and find it confusing.
- In R&D biotech investing, many investors who may not have a science background rely heavily on the integrity & scientific expertise of the company to understand the trial results.
- I think it's a recipe for disaster when the company and/or investors lose clarity & objectivity while the wider market looks on with detached, skeptical eyes.
For further details see:
Annovis Bio's Latest P2a Alzheimer's Biomarkers Presentation Leaves Investors Confused